CALGB-30506
|
CALGB
|
A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients with Early Stage Non-Small Cell Lung Cancer Associated with Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
CALGB-30607
|
CALGB
|
Randomized; Phase III; Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511; IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced; Stage IIIB/IV Non-Small Cell Lung Cancer
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
CALGB-30610
|
CALGB
|
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
CALGB-30801
|
CALGB
|
A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
CALGB-40101
|
CALGB
|
Cyclophosphamide and Doxorubicin (CA X 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
CALGB-40302
|
CALGB
|
Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized; Double-Blind; Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
CALGB-40502
|
CALGB
|
A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer<br>
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
CALGB-40503
|
CALGB
|
Endocrine Therapy with or without ANTI-VEGF Therapy: A Randomized; Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
CALGB-40601
|
CALGB
|
Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
CALGB-49808
|
CALGB
|
A 2 X 2 X 2 Factorial Randomized Phase III Trial of Multimodality Therapy Comparing 4 Cycles of Doxorubicin and Cyclophosphamide with or without Dexrazoxane (AC +/- Z) Followed by 12 Weeks of Weekly Paclitaxel with or without Trastuzumab (T H) Followed by Local Therapy Followed by 40 Weeks of Weekly Trastuzumab or none in Women with HER-2+ STAGE IIIA; IIIB or Regional Stage IV Breast Cancer **ADMINISTRATIVELY COMPLETED as of December 15; 2002**
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|